Respiratory Medicine
Volume 104, Issue 3 , Pages 434-439 , March 2010

Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer

  • Young Hak Kim

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, sakyo-ku, Kyoto 606-8507, Japan
    • Corresponding Author InformationCorresponding author at: Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, sakyo-ku, Kyoto 606-8507, Japan. Tel.: +81 75 751 3830; fax: +81 75 751 4643.
    • ,
  • Kiyotaka Yoh

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • ,
  • Seiji Niho

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • ,
  • Koichi Goto

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • ,
  • Hironobu Ohmatsu

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • ,
  • Kaoru Kubota

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan
    • ,
  • Yutaka Nishiwaki

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

Received 13 February 2009 ,Accepted 22 October 2009.

References 

  1. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?. Lung Cancer. 2002;38(Suppl. 2):S45–S50
  2. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23(13):3125–3137
  3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98
  4. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007;18(2):317–323
  5. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest. 2005;128(2):947–957
  6. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol. 2007;25(14):1898–1907
  7. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995;13(3):235–252
  8. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. Thorax. 1996;51(6):564–568
  9. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer?. Chest. 2000;117(5):1239–1246
  10. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–2067
  11. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst. 1999;91(1):66–72
  12. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103
  13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 2000;18(12):2354–2362
  14. Kelly K, Giarritta S, Akerley W, et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest oncology trials 9509 and 9308. Proc Am Soc Clin Oncol. 2001;20:329a
  15. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst. 2002;94(3):173–181
  16. Langer CJ, Vangel J, Schiller DP, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol. 2003;22:639a
  17. Goto K, Nishiwaki Y, Saijo N, et al. The four-arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC): a subgroup analysis in elderly patients. Proc Am Soc Clin Oncol. 2006;24:7115a
  18. Tsukada H, Yokoyama A, Nishiwaki Y, et al. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. Proc Am Soc Clin Oncol. 2007;25:7629
  19. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008;13(Suppl. 1):28–36

PII: S0954-6111(09)00353-9

doi: 10.1016/j.rmed.2009.10.020

Respiratory Medicine
Volume 104, Issue 3 , Pages 434-439 , March 2010

Article Tools

* Image Usage & Resolution